Antibody-Drug Conjugates in Breast Cancer: Enhertu vs. Trodelvy in EU Market
This article compares Enhertu and Trodelvy, two leading antibody-drug conjugates, in their effectiveness for breast cancer treatment in the EU market.
Medically Reviewed
by Dr. James Morrison, Chief Medical Officer (MD, FACP, FACC)
Reviewed on: May 01, 2026
Key Takeaways
- ADCs transforming breast cancer therapy: Antibody-drug conjugates (ADCs) are reshaping European breast cancer treatment, with the European Medicines Agency (EMA) validating datopotamab deruxtecan (DATROWAY®) on December 18, 2025, as a first-line monotherapy option for triple-negative breast cancer patients ineligible for immunotherapy.
- Clinical efficacy milestone: Datopotamab deruxtecan demonstrated statistically significant improvements in overall survival and progression-free survival versus chemotherapy in the TROPION-Breast02 phase 3 trial, expanding first-line ADC options beyond established agents.
- Market segmentation by antigen target: The EU breast cancer ADC landscape now spans HER2-positive disease (trastuzumab deruxtecan), Trop-2-targeting agents for triple-negative breast cancer (sacituzumab govitecan, datopotamab deruxtecan), creating distinct competitive positioning based on patient biology.
- Treatment paradigm shift: The introduction of datopotamab deruxtecan as first-line monotherapy for immunotherapy-ineligible TNBC patients addresses a previously underserved population, potentially altering treatment algorithms across EU5 markets.
The European breast cancer market is experiencing a pivotal expansion in antibody-drug conjugate (ADC) options following the EMA's December 2025 validation of datopotamab deruxtecan for first-line use in unresectable or metastatic triple-negative breast cancer. This approval complements established ADCs including trastuzumab deruxtecan (Enhertu) for HER2-positive disease and sacituzumab govitecan (Trodelvy) for triple-negative subtypes, creating a differentiated competitive landscape driven by antigen-specific targeting and clinical positioning. Why it matters: The EMA's validation of datopotamab deruxtecan as a first-line monotherapy expands treatment options for TNBC patients ineligible for checkpoint inhibitor-based immunotherapy, addressing a significant clinical gap in the European market.
Drug Overview
Antibody-drug conjugates represent a precision oncology class designed to selectively deliver cytotoxic payloads to cancer cells expressing tumor-associated antigens. The three leading agents in the European breast cancer market employ distinct targeting strategies:
Trastuzumab deruxtecan (Enhertu) is a HER2-directed ADC combining trastuzumab with a deruxtecan payload, approved for HER2-positive breast cancer across multiple lines of therapy. The mechanism leverages HER2 overexpression as the primary antigen target, enabling selective tumor cell destruction while minimizing off-target toxicity.
Sacituzumab govitecan (Trodelvy) targets Trop-2, a tumor-associated calcium signal transducer expressed across multiple solid tumors including triple-negative breast cancer. The conjugate delivers a topoisomerase I inhibitor payload, offering an alternative mechanism for TNBC patients, particularly in later treatment lines.
Datopotamab deruxtecan (DATROWAY®) also targets Trop-2 but employs a distinct linker technology and deruxtecan payload configuration. The EMA validation on December 18, 2025, marks its entry into the European market as a first-line monotherapy option for unresectable or metastatic TNBC patients ineligible for PD-1/PD-L1 inhibitor-based therapy.
Clinical Insights
Datopotamab deruxtecan's EMA validation was based on efficacy and safety data from the TROPION-Breast02 phase 3 trial, which evaluated first-line monotherapy in unresectable or metastatic triple-negative breast cancer. The trial enrolled patients ineligible for checkpoint inhibitor therapy, representing a distinct patient population with limited treatment alternatives.
Primary efficacy endpoints: Datopotamab deruxtecan demonstrated statistically significant improvements in overall survival (OS) and progression-free survival (PFS) compared with standard chemotherapy. The trial design allowed EMA to establish clinical benefit in a population previously dependent on conventional cytotoxic regimens or off-label ADC use.
Compared with sacituzumab govitecan, which is positioned primarily in later lines of TNBC therapy, datopotamab deruxtecan's first-line validation represents a shift toward earlier ADC integration into treatment algorithms. Trastuzumab deruxtecan remains the leading ADC for HER2-positive breast cancer, with established clinical superiority over standard HER2-targeted therapies, though specific comparative trial data and hazard ratios are not detailed in current regulatory summaries.
The clinical profile of datopotamab deruxtecan in TROPION-Breast02 establishes a new standard-of-care option for immunotherapy-ineligible TNBC patients, addressing a significant unmet need in the European market where PD-1/PD-L1 inhibitors are not universally tolerated or accessible.
Regulatory Context
Datopotamab deruxtecan received a Type II Variation from the EMA on December 18, 2025, expanding its approved indication to include first-line monotherapy for unresectable or metastatic triple-negative breast cancer in patients ineligible for PD-1/PD-L1 inhibitors. This regulatory pathway reflects the EMA's recognition of clinical benefit in a defined patient population with limited therapeutic alternatives.
The approval follows completion of the TROPION-Breast02 phase 3 trial, which met its primary efficacy endpoints for OS and PFS. The EMA's decision underscores the regulatory body's commitment to accelerating ADC approvals in breast cancer subtypes where unmet clinical needs persist, particularly for patients with contraindications to immunotherapy.
Trastuzumab deruxtecan and sacituzumab govitecan maintain established marketing authorizations in the EU, with trastuzumab deruxtecan holding approvals across multiple lines of HER2-positive breast cancer therapy. The regulatory landscape reflects a broader EMA strategy of enabling ADC development as precision oncology agents, with approvals increasingly stratified by patient eligibility criteria and biomarker status.
What to watch next: Ongoing EMA assessments of label expansions for existing ADCs, potential combination therapy studies integrating ADCs with targeted agents or immunotherapies in defined patient populations, and regulatory submissions from competing ADC candidates targeting HER2 or Trop-2 in breast cancer.
Market Impact
The European breast cancer ADC market is segmented by antigen specificity and clinical positioning, creating distinct competitive niches. Trastuzumab deruxtecan dominates the HER2-positive segment, where its superior efficacy over standard HER2-targeted therapies has established market leadership across multiple lines of therapy. The HER2-positive breast cancer population in Europe encompasses approximately 15–20% of all breast cancer diagnoses, representing a substantial addressable market for HER2-directed ADCs.
Triple-negative breast cancer, representing 10–15% of breast cancer diagnoses, has historically relied on chemotherapy and emerging immunotherapy options. The entry of datopotamab deruxtecan as a first-line monotherapy creates a competitive dynamic with sacituzumab govitecan, which is primarily positioned in later treatment lines. Datopotamab deruxtecan's first-line indication potentially shifts treatment paradigms by offering an earlier ADC intervention point for immunotherapy-ineligible patients.
Pricing and reimbursement considerations significantly influence ADC uptake across EU5 markets (France, Germany, Italy, Spain, United Kingdom). ADCs typically command premium pricing relative to standard chemotherapy, reflecting their precision targeting and improved efficacy profiles. However, Health Technology Assessment (HTA) bodies across Europe increasingly scrutinize cost-effectiveness ratios, requiring manufacturers to demonstrate incremental benefit justifying premium price points.
The competitive landscape among Trop-2-targeting ADCs (sacituzumab govitecan versus datopotamab deruxtecan) will likely intensify as both agents compete for market share in TNBC. Differentiation will depend on clinical trial data, real-world efficacy comparisons, tolerability profiles, and HTA recommendations across EU member states. Trastuzumab deruxtecan's established market position in HER2-positive disease provides a template for successful ADC adoption, though its higher pricing may face resistance in cost-constrained healthcare systems.
Future Outlook
The ADC pipeline in breast cancer continues to expand, with multiple candidates in clinical development targeting HER2, Trop-2, and emerging antigens. Ongoing trials are evaluating ADC combinations with immunotherapies, targeted agents, and conventional chemotherapy, potentially reshaping treatment algorithms and expanding ADC utility beyond monotherapy settings.
Key areas of clinical evolution include:
- Biomarker refinement: Enhanced patient selection through predictive biomarkers for ADC response, including tumor antigen expression levels, baseline immune status, and resistance mechanisms, may improve clinical outcomes and optimize treatment sequencing.
- Combination strategies: Integration of ADCs with PD-1/PD-L1 inhibitors in immunotherapy-eligible populations, and potential combinations with targeted therapies (CDK4/6 inhibitors, hormone therapies) in HR-positive disease, may unlock additional clinical benefit.
- Early-line positioning: Expansion of ADC approvals into neoadjuvant and adjuvant settings, moving beyond metastatic disease, could significantly broaden market opportunity and patient impact.
- Resistance mechanisms: Clinical research into mechanisms of ADC resistance, including antigen loss and efflux pump upregulation, will inform next-generation ADC design and combination approaches.
The EMA's adaptive regulatory pathways, including conditional approvals and accelerated assessment, are likely to continue facilitating ADC development in unmet need areas. Datopotamab deruxtecan's rapid EMA validation demonstrates regulatory willingness to prioritize ADCs addressing immunotherapy-ineligible populations, setting a precedent for future submissions in similarly underserved patient cohorts.
European healthcare budget implications are substantial, as widespread ADC adoption will increase oncology spending. Payers across EU5 markets will demand robust health economic evidence, including cost-effectiveness analyses and budget impact models, to justify ADC reimbursement at premium price points relative to chemotherapy and other standard-of-care options.
Frequently Asked Questions
How does datopotamab deruxtecan differ from sacituzumab govitecan, given that both target Trop-2?
Although both agents target Trop-2, they employ distinct linker technologies and payload configurations. Datopotamab deruxtecan uses a deruxtecan payload, while sacituzumab govitecan delivers a topoisomerase I inhibitor. Critically, datopotamab deruxtecan received EMA validation for first-line monotherapy in unresectable or metastatic TNBC, whereas sacituzumab govitecan is primarily positioned in later treatment lines. This clinical positioning difference reflects their distinct trial designs and regulatory pathways, creating separate market opportunities rather than direct head-to-head competition in all settings.
Why is trastuzumab deruxtecan considered the leading ADC in the European breast cancer market?
Trastuzumab deruxtecan targets HER2-positive breast cancer, which comprises 15–20% of all breast cancer diagnoses. Its demonstrated superior efficacy over standard HER2-targeted therapies, combined with established approvals across multiple lines of therapy and strong clinical evidence, has positioned it as the market-leading ADC in Europe. The HER2-positive segment represents a substantial and well-defined patient population with clear clinical need.
What is the clinical significance of datopotamab deruxtecan's first-line approval for immunotherapy-ineligible TNBC patients?
Approximately 10–15% of breast cancer patients have triple-negative disease, and a meaningful subset are ineligible for PD-1/PD-L1 inhibitor therapy due to contraindications, comorbidities, or prior toxicity. Datopotamab deruxtecan's EMA validation addresses this previously underserved population by offering a first-line monotherapy alternative to chemotherapy, potentially improving outcomes and reducing reliance on conventional cytotoxic regimens in this high-risk subtype.
How will HTA decisions across EU5 markets influence ADC adoption and pricing?
Health Technology Assessment bodies in France, Germany, Italy, Spain, and the United Kingdom conduct independent cost-effectiveness analyses and reimbursement recommendations. ADCs typically command premium pricing relative to chemotherapy, requiring manufacturers to demonstrate incremental clinical benefit and acceptable cost-effectiveness ratios (often €30,000–€50,000 per quality-adjusted life year in European markets). HTA recommendations directly influence payer decisions and patient access, making them critical determinants of ADC market penetration across the EU.
Are there ongoing trials evaluating ADC combinations with immunotherapies in breast cancer?
The ADC pipeline includes multiple studies exploring combination strategies, though specific trial names and enrollment data are not detailed in current regulatory summaries. Clinical interest focuses on combining ADCs with PD-1/PD-L1 inhibitors in immunotherapy-eligible populations, and potentially with CDK4/6 inhibitors or hormone therapies in HR-positive disease. These combination approaches aim to enhance clinical benefit beyond monotherapy, though regulatory approval timelines and efficacy data remain to be established.
References
- European Medicines Agency. Datopotamab deruxtecan (DATROWAY®) Type II Variation approval for first-line monotherapy in unresectable or metastatic triple-negative breast cancer. December 18, 2025.
References
- European Medicines Agency. EMA approval. Accessed 2026-05-01.
European Regulatory Correspondent
Dr. Marcus Weber is a cardiologist and former EMA rapporteur with expertise in European pharmaceutical policy. He holds degrees from Heidelberg University and has advised on over 50 marketing authoriz...
